Researchers reveal developmental mechanisms behind rare bone marrow disorder
(Charit é - Universit ä tsmedizin Berlin) Myelodysplastic syndrome is an umbrella term used to describe disorders characterized by the bone marrow's inability to produce normal blood cells. Researchers from Charit é - Universit ä tsmedizin Berlin have found that a mutation in a specific tumor suppressor gene is one possible reason why children with a very rare genetic disorder develop myelodysplastic syndrome. Results from this research have been published in the current edition of the Journal of Clinical Investigation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2017 Category: Global & Universal Source Type: news
FibroGen to initiate Phase II/III trial of roxadustat to treat MDS related anaemia in China
US-based biopharmaceutical firm FibroGen has secured approval from the China Food and Drug Administration (CFDA) to initiate a Phase II/III clinical trial of roxadustat to treat anaemia associated with lower risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2017 Category: Pharmaceuticals Source Type: news
UAMS Gets $1.7M NIH Grant to Study Therapy Against Blood Cancer
The University of Arkansas for Medical Sciences has received a $1.7 million grant from the National Institutes of Health to study a potential new therapy to reduce the risk of blood cancer caused by ionizing radiation.
Dr. Daohong Zhou received the grant for his team's work addressing whether the ability to restore the fitness of a person’s blood cell-generating cells after radiation can prevent blood cancers like leukemia or bone marrow disorders.
UAMS said that out of all cases of myelodysplastic syndrome and leukemia, up to 20 percent are considered to be caused by ionizing radiation exposure and chemotherapy.&nbs...
Source: Arkansas Business - Health Care - March 30, 2017 Category: American Health Source Type: news
Researchers show p300 protein may suppress leukemia in MDS patients
(University of Miami Miller School of Medicine) Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that p300, a protein that increases gene expression by attaching acetyl molecules to DNA, may stop myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2017 Category: Cancer & Oncology Source Type: news
EPREX ® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
French Health Authority ANSM grants approval in the Mutual Recognition Procedure; the relevant health authorities are required to implement the new indication within 30 days (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 24, 2017 Category: Pharmaceuticals Source Type: news
Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes
This video explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes. (Source: CancerNetwork)
Source: CancerNetwork - March 16, 2017 Category: Cancer & Oncology Authors: Valeria Santini, MD Tags: Myelodysplastic Syndromes Videos Hematologic Malignancies Source Type: news
FDA grants orphan drug designation to Boehringer Ingelheim ’s antibody BI 836858
The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim ’s anti-CD33 monoclonal antibody, BI 836858, which is being investigated in the treatment of myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 13, 2017 Category: Pharmaceuticals Source Type: news
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week ' s topics include sickle cell trait and HbA1c, carcinogen levels and e-cigarettes, mutations and myelodysplastic syndrome, and kids ingesting pet medicines (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 11, 2017 Category: American Health Source Type: news
Eltrombopag Improved Platelet Counts in Thrombocytopenic MDS Patients
The use of the thrombopoietin receptor agonist eltrombopag was clinically effective at raising platelet counts in patients with lower-risk myelodysplastic syndromes with severe thrombocytopenia. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news
Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome
(Dana-Farber Cancer Institute) A single blood test and basic information about a patient's medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, according to new research by scientists at Dana-Farber Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 8, 2017 Category: Cancer & Oncology Source Type: news
Mayo Clinic: Association between autoimmune disease and bone marrow disorders
(Mayo Clinic) Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2017 Category: Global & Universal Source Type: news
Mayo Clinic researchers find association between therapy for autoimmune disease and bone marrow disorders
PHOENIX ? Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. Researchers analyzed more than 40,000 [...] (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - February 1, 2017 Category: Hospital Management Source Type: news
Devon boy is only child in Britain with a debilitating disease which is baffling doctors
Brave Oliver Brown has rare bone marrow disorder Myelodysplastic Syndrome. The youngster, from Plymouth in Devon, will have a transplant while doctors race to learn more about the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - January 14, 2017 Category: Consumer Health News Source Type: news
Outlook for 2017: Acute Leukemias, MDS, and CLL
This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of acute leukemias, myelodysplastic syndromes, and chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 26, 2016 Category: Cancer & Oncology Authors: Guido Marcucci, MD Tanya Siddiqi, MD Tags: Conferences/Hematologic Malignancies Year in Review 2016 Source Type: news
Chinese herbal treatment shows signs of effectiveness in bone marrow recovery
FINDINGSUCLA researchers have found that a Chinese herbal regimen called TSY-1 (Tianshengyuan-1) increased telomerase activity in normal blood cells but decreased it in cancer cells. Telomerase is an enzyme responsible for the production of telomeres, which play an important role in the regulation of normal cell division. These results indicate that telomerase-based treatments may play an important role in treating both blood cell deficiency and cancer.BACKGROUNDMore than 80 percent of cancers have increased telomerase activity, and other medical conditions are also associated with decreased or abnormal telomerase function...
Source: UCLA Newsroom: Health Sciences - December 14, 2016 Category: Universities & Medical Training Source Type: news
